Co-delivery of Cisplatin(IV) and Capecitabine as an Effective and Non-toxic Cancer Treatment

Xiao Xiao; Ting Wang; Leijiao Li; Zhongli Zhu; Weina Zhang; Guihua Cui; Wenliang Li

doi:10.3389/fphar.2019.00110

Co-delivery of Cisplatin(IV) and Capecitabine as an Effective and Non-toxic Cancer Treatment

Front Pharmacol. 2019 Feb 19:10:110. doi: 10.3389/fphar.2019.00110. eCollection 2019.

Authors

Xiao Xiao^{1

2}, Ting Wang³, Leijiao Li⁴, Zhongli Zhu⁴, Weina Zhang⁵, Guihua Cui^{1

2}, Wenliang Li^{1

2}

Affiliations

¹ School of Pharmacy, Jilin Medical University, Jilin, China.
² Center for Biomaterials, Jilin Medical University, Jilin, China.
³ Department of the Gastrointestinal Surgery, The First Hospital of Jilin University, Changchun, China.
⁴ Jilin Provincial Science and Technology Innovation Center of Optical Materials and Chemistry, School of Chemistry and Environmental Engineering, Changchun University of Science and Technology, Changchun, China.
⁵ Common Subjects Department, Shangqiu Medical College, Henan, China.

Abstract

A strategy for preparing composite micelles (CM) containing both cisplatin(IV) [CisPt(IV)] prodrug and capecitabine using a co-assembly method is described in this study. The CM are capable of an effective release of the anticancer drug cisplatin(II) [CisPt(II)] and capecitabine via acid hydrolysis once they are internalized by cancer cells. Moreover, the CM display a synergistic effect in vitro and the combination therapy in the micellar dosage form leads to reduced systemic toxicity and enhanced antitumor efficacy in vivo.

Keywords: cancer treatment; capecitabine; cisplatin(IV); co-delivery; composite micelles.